I have been tracking this Co since 2005-06.It was suppose to have prospered as a great pharma co but that didn't happened.But since last 6 months I am reading good news on this upcoming pharma Co.
I would not write what Co was going through in last 6 months .That I keep it for my readers to explore what this Pharma Co was doing.
But today when I read news in BS I can't resist myself to write on it.
I am pasting that article of BS here.....
Pfizer to source 40 off-patent cancer care drugs from Strides
BS REPORTER Bangalore, 6 January
Global pharma major Pfizer is to source source 40 off-patent (generic) cancer care products from Bangalore-based Strides Arcolab and sell the products in the United States.
Announcing this deal today, the two companies said they had formed a collaboration wherein Pfizer will commercialise off-patent sterile injectable and oral products in the US through its Established Products Business Unit (EPBU), which focuses on generics. The EPBU launched its US injectables team less than 10 months earlier and is already marketing products there.
These dosage-form cancer care products will be licensed and supplied by Strides and Onco Laboratories Ltd and Onco Therapies Ltd, two joint ventures between Strides and Aspen, South Africa, in which each has a 50 per cent ownership interest. The financial terms of the supply agreement were not disclosed.
Strides, with a top line of close to Rs 2,000 crore, will deliver the 40 off-patent products, many of which are oncology therapeutics, to healthcare providers and patients in the US, by joining Pfizer’s commercial infrastructure with Strides’s manufacturing capabilities. The first of the products commercialised under this collaboration is expected to be launched in 2010.
“This Strides collaboration is new and exciting, and we are encouraged about the potential of this relationship,” said David Simmons, president and general manager of Pfizer’s EPBU. “In addition, this agreement brings the total number of products in-licensed by our Established Products Business Unit to more than 200 — resulting in a total business unit portfolio of approximately 600 products for patients.”
Stride Aroclab has made inroads in Cancer drugs and has been able to have MNC like Pfizer collobarating for Off Patenet drug in cancer.
That is to me a major breakthrough for Stride Arcolab.Seems happy days are here again for Stride Aroclab.A 2000 cr topline pharma Co going just at Rs 234....! Wow!The patent are no less then 40! That is big....numbers.
Rest of the DD I would like to be done by my readers.......Promoters holdoing 25.73% and other Corp investor holding 54.31 % , means 80% is with biggies and hence only 20% remains with public.....that is added trigger for this upcoming Pharma Co...